CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis
For treating non-small cell lung cancer (NSCLC), liquid biopsy (LB) was analyzed using...
Read More
Meeting Coverage
Adjuvant Chemotherapy in High-Risk, Early-Stage NSCLC with Clinical and Pathologic Features Reevaluated
Surgical resection is the preferred treatment for early-stage non-small cell lung cancer (NSCLC),...
Read More
FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS
Frequent falls and the fear of falling (FOF) are significant challenges experienced by individuals...
Read More
Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings
Researchers conducted a study to examine the effects of mindfulness-based stress reduction (MBSR)...
Read More
Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis
Fatigue is a common and debilitating symptom among individuals with multiple sclerosis (MS)....
Read More
Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment
Tolebrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), has been specifically...
Read More
MRI Results of Tolebrutinib Long-Term Safety Extension Study in Relapsing MS
Tolebrutinib, a potent inhibitor of Bruton tyrosine kinase that can cross the blood-brain barrier,...
Read More
Why Attend CMSC
From CMSC’s Annual Meeting brochure: The Consortium of Multiple Sclerosis Centers (CMSC) has...
Read More
Quick Glance At CMSC Schedule
Take a look at CMSC’s Wednesday schedule: 8:00 am – 9:30 am ISS1 Independently...
Read More
MS Therapies Not Associated With Pregnancy Complications
A registry data analysis concluded that most disease-modifying therapies for MS are not associated...
Read More
5th Annual More About MS Patient Program
Managing Invisible Symptoms | June 2, 2023 “More About MS: Taking Charge of Your MS Care” will be...
Read More
Ancillary Educational Events
Ancillary events are functions held adjacent to the ASCO Annual Meeting, including, but not...
Read More
Communities of Practice
Connect with colleagues that share your passion and goals through one of ASCO’s new Communities of...
Read More
ASCO Voices
ASCO Voices continues to be one of the most compelling sessions offered at the ASCO Annual...
Read More
Q&A: Can Remyelination of Axons Restore Vision in MS?
The VISIONARY-MS trial showed that CNM-Au8, an oral liquid suspension of gold nanoparticles,...
Read More
Orphan Non-Coding RNAs Have Potential for Early Identification of NSCLC
Orphan non-coding RNAs demonstrated efficacy for accurate, sensitive, and early detection of...
Read More
SphK2 Shows Promise for Overcoming NSCLC Tumor Progression
Sphingosine kinase 2 may be a promising clinical target for overcoming EGFR-TKI resistance and...
Read More
Stem Cell Therapy Improves Walking in More Advanced Progressive MS
Intrathecal mesenchymal stem cell-neural progenitor therapy failed to significantly improve the...
Read More
Gold Nanocrystals May Be Effective as Adjunctive MS Therapy
The VISIONARY-MS study suggests catalytically active gold nanocrystals given in addition to...
Read More
Teriflunomide Prevents Conversion to MS in Patients With RIS
In people with radiologically isolated syndrome, teriflunomide resulted in a 62% risk decline for...
Read More